Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 7/20 | 0.43 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19156000 | 0.87 | DAO (0.50) | DAOMAOAKDM1A | |
| SCHEMBL3657309 | 0.82 | KMO (0.49) | DAOMAOASERPINE1 | |
| SCHEMBL25857785 | 0.81 | MAOA (0.43) | MAOAKDM1ARCOR1MAOB | |
| SCHEMBL3662438 | 0.77 | PIK3CA (0.41) | MAOAKDM1ARCOR1 | |
| SCHEMBL3660247 | 0.77 | HPGD (0.55) | MAOAKDM1A | |
| SCHEMBL3664581 | 0.77 | HPGD (0.55) | MAOAKDM1A | |
| SCHEMBL21471638 | 0.76 | KDM1A (0.66) | MAOAKDM1ARCOR1MAOB | |
| SCHEMBL13124473 | 0.73 | HPGD (0.49) | MAOAKDM1AMAOB | |
| SCHEMBL3865147 | 0.72 | HSD11B1 (0.57) | MAOAKDM1A | |
| SCHEMBL3865150 | 0.72 | HSD11B1 (0.57) | MAOAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| EP-2229374-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009074789-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074789-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | DAO 1770/4885MAOA 1833/4885KDM1A 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.